Background
Ramatercept (ACE-031) is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy.• Targeting the myostatin signaling pathway to treat muscle loss and metabolic dysfunction., PMID:33938454• Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member., PMID:9139826• GDF8 inhibition enhances musculoskeletal recovery and mitigates posttraumatic osteoarthritis following joint injury., PMID:38019905• Growth differentiation factor 8 down-regulates pentraxin 3 in human granulosa cells., PMID:25641196• Growth differentiation factor myostatin regulates epithelial-mesenchymal transition genes and enhances invasion by increasing serine protease inhibitors E1 and E2 in human trophoblast cells., PMID:37738042• Growth differentiation factor 8 induces SKOV3 ovarian cancer cell migration and E-cadherin down-regulation., PMID:27481097• Circulating Growth Differentiation Factor 11/8 Levels Decline With Age., PMID:26489925• Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11., PMID:30814254• Effects of growth differentiation factor 8 on steroidogenesis in human granulosa-lutein cells., PMID:26607022• Molecular characterization of latent GDF8 reveals mechanisms of activation., PMID:29348202